Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peptides and glycopeptides | 4234 | 1350810-60-4 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
an erythropoiesis stimulating agent
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 27, 2012 | FDA | TAKEDA PHARMS USA |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | B03XA04 | BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS OTHER ANTIANEMIC PREPARATIONS Other antianemic preparations |
| FDA PE | N0000009319 | Increased Erythroid Cell Production |
| FDA EPC | N0000175665 | Erythropoiesis-stimulating Agent |
| CHEBI has role | CHEBI:66894 | erythropeotin receptor agonist |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia in chronic kidney disease | indication | 707323002 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 10MG BASE/ML (EQ 10MG BASE/ML) | OMONTYS | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 10MG BASE/ML (EQ 10MG BASE/ML) | OMONTYS | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | OMONTYS | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | OMONTYS | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7550433 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) | OMONTYS PRESERVATIVE FREE | TAKEDA PHARMS USA | N202799 | March 27, 2012 | DISCN | SOLUTION | INTRAVENOUS, SUBCUTANEOUS | 7919461 | June 2, 2026 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Erythropoietin receptor | Membrane receptor | AGONIST | IC50 | 10.43 | IUPHAR | DRUG LABEL |
| ID | Source |
|---|---|
| D09946 | KEGG_DRUG |
| 913976-27-9 | SECONDARY_CAS_RN |
| 4031520 | VANDF |
| CHEBI:66889 | CHEBI |
| CHEMBL2107866 | ChEMBL_ID |
| CHEMBL1963684 | ChEMBL_ID |
| C556270 | MESH_SUPPLEMENTAL_RECORD_UI |
| C514771 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7447 | IUPHAR_LIGAND_ID |
| DB08894 | DRUGBANK_ID |
| JX56W9N61Q | UNII |
| 1248797 | RXNORM |
| 188373 | MMSL |
| 28476 | MMSL |
| d07857 | MMSL |
| 014268 | NDDF |
| C3179929 | UMLSCUI |
| 9304 | INN_ID |
| 1185870-58-9 | SECONDARY_CAS_RN |
| JX56W9N61Q | INXIGHT DRUGS |
None